<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170314033069N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-13</date_registration>
      <primary_sponsor>Vice President of Research Guilan university of medical sciences</primary_sponsor>
      <public_title>Comparison of ultrasound and fluoroscopic guided intra-articular sacroiliac injection in patients with sacroiliac joint disorder</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effectiveness of ultrasound-guided versus fluoroscopy-guided sacroiliac joint intra-articular injection in patients with sacroiliac joint disorders</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>122</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53075</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Individuals will be grouped by block randomization. First, 4 blocks will be prepared as follows:
AABB, ABAB, ABBA, BBAA, BABA, BAAB
These blocks are then randomly selected and individuals will be divided into two groups according to A and B: ultrasound and fluoroscopy. This will be repeated continuously, Blinding description: This study is single-blinded ,patients and the physician performing the work are aware of the treatment for each patient and the evaluator is unaware.</study_design>
      <phase>2</phase>
      <hc_freetext>Chronic pain of sacroiliac joint.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group Sacroiliac joint injection with ultrasound guide: patients will be positioned prone with a pillow under their abdomen. A low-frequency curved transducer (4 to 6 megahertz) perpendicular to the skin on the external sacrum will be placed in the midline with a cross-sectional view to detect the sacral hiatus. The probe will be moved laterally until the lateral edge of the sacrum is visible, then moved toward the caudal to find the inner direction of the iliac bone. At this location, the sacroiliac joint appears as a wedge-shaped hypoechoic structure. The suitable place for injection is at the level of the second sacral foramen, which is approximately 2-3 centimeters above the caudal surface of the sacroiliac joint. lidocaine1% (manufacturer: Caspian tamin Company. made in Iran) will be injected subcutaneously into the inner edge of the probe. A needle with a 22 gauge in-plane and oblique and anterior position will be inserted into the joint. After the needle is inserted deep into the iliac bone, it is no longer visible with an ultrasound. The popping sound is felt when the synovial joint ruptures. Intervention 2: Intervention group Sacroiliac joint injection with fluoroscopic guide: Initially, standard monitoring will be performed throughout the procedure. The patient will be positioned in the prone with the head turned to one side. A pillow is placed under the abdomen to bend the waist. Under the direct anterior-posterior view, the sacroiliac joint shows several lines that point toward the craniocerebral cortex in a semi-parallel pattern. The lateral line shows the ventral or anterior margin of the joint, and the inner line represents the dorsal or posterior margin of the joint. For a better view of the lower areas of the upper posterior iliac and iliac crest, the C-arm is initially rotated 30 degrees from the caudal to the axial plate. The C-arm is angled, usually between 5 and 20 degrees in the opposite direction, until the space of the lower joint is clearly defined. The target area is located along the lower posterior part of the joint 1 to 2 centimeters towards the cephalad from the most caudal point. The target area will be prepared and draped with the usual sterile method. The skin is anesthetized with 1 to 2 cc of lidocaine 1% through needle number 25. Spinal needle Number 22 travels coaxially to the lower bridge of the sacroiliac joint and will be confirmed by giving alternating images at regular intervals (every 2 to 4 millimeters of the needle advance). When the posterior surface of the sacroiliac joint is contacted, the needle goes to the point where it ruptures the joint capsule. Resistance changes will be commonly felt as the needle passes through the capsular tissue, and the tip of the needle usually deflects slightly when it strikes the surface of the ilium.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Not decided yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Gelareh Biazar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Research Center, Alzahra Hospital, Namjoo Street, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 3332 9524</telephone>
        <email>gelarehbiazar1386@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Gelareh Biazar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Research Center, Alzahra Hospital, Namjoo Street, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654839</zip>
        <telephone>+98 13 3332 9524</telephone>
        <email>gelarehbiazar1386@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 18 years old who have been nominated for sacroiliac joint injection due to persistent sacroiliac joint pain
Out of 7 tests in clinical examinations, at least 4 examinations are positive
The patient's average pain over the past week is at least 3 out of 10 (in Numerical Rating scale)
The patient has persistent pain for at least 6 weeks and does not respond to at least one or two conservative treatments such as oral medications, anti-inflammatory drugs, analgesics, muscle relaxants, and physical therapies.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Complaints of lower back pain so that the distinction between sacroiliac joint and L5 / S1 fastogenic back pain is indistinguishable.
Dye contrast sensitivity
Contraindications to fluoroscopy
Active lesion in structures of sacroiliac joint such as lumbar spine pathologies and hip pathology
Secondary orthopathy to rheumatoid causes
Abnormal anatomy
Infection, bleeding and trauma at the site
Previous history of intro-articular injection
Active inflammatory diseases
Untreated coagulopathies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M46.98</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group Sacroiliac joint injection with ultrasound guide: patients will be positioned prone with a pillow under their abdomen. A low-frequency curved transducer (4 to 6 megahertz) perpendicular to the skin on the external sacrum will be placed in the midline with a cross-sectional view to detect the sacral hiatus. The probe will be moved laterally until the lateral edge of the sacrum is visible, then moved toward the caudal to find the inner direction of the iliac bone. At this location, the sacroiliac joint appears as a wedge-shaped hypoechoic structure. The suitable place for injection is at the level of the second sacral foramen, which is approximately 2-3 centimeters above the caudal surface of the sacroiliac joint. lidocaine1% (manufacturer: Caspian tamin Company. made in Iran) will be injected subcutaneously into the inner edge of the probe. A needle with a 22 gauge in-plane and oblique and anterior position will be inserted into the joint. After the needle is inserted deep into the iliac bone, it is no longer visible with an ultrasound. The popping sound is felt when the synovial joint ruptures.</i_keyword>
      <i_keyword>Intervention group Sacroiliac joint injection with fluoroscopic guide: Initially, standard monitoring will be performed throughout the procedure. The patient will be positioned in the prone with the head turned to one side. A pillow is placed under the abdomen to bend the waist. Under the direct anterior-posterior view, the sacroiliac joint shows several lines that point toward the craniocerebral cortex in a semi-parallel pattern. The lateral line shows the ventral or anterior margin of the joint, and the inner line represents the dorsal or posterior margin of the joint. For a better view of the lower areas of the upper posterior iliac and iliac crest, the C-arm is initially rotated 30 degrees from the caudal to the axial plate. The C-arm is angled, usually between 5 and 20 degrees in the opposite direction, until the space of the lower joint is clearly defined. The target area is located along the lower posterior part of the joint 1 to 2 centimeters towards the cephalad from the most caudal point. The target area will be prepared and draped with the usual sterile method. The skin is anesthetized with 1 to 2 cc of lidocaine 1% through needle number 25. Spinal needle Number 22 travels coaxially to the lower bridge of the sacroiliac joint and will be confirmed by giving alternating images at regular intervals (every 2 to 4 millimeters of the needle advance). When the posterior surface of the sacroiliac joint is contacted, the needle goes to the point where it ruptures the joint capsule. Resistance changes will be commonly felt as the needle passes through the capsular tissue, and the tip of the needle usually deflects slightly when it strikes the surface of the ilium.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intensity of pain. Timepoint: Before the procedure, zero time of the procedure, 15 minutes and 24 hours after the procedure. Method of measurement: Based on the Numerical Rating Scale (a scale for pain).</prim_outcome>
      <prim_outcome>Duration of the procedure. Timepoint: At the end of procedure. Method of measurement: Measuring time based on minutes.</prim_outcome>
      <prim_outcome>Complications of the procedure (hypotension,urticaria). Timepoint: During the procedure and at the end. Method of measurement: Blood pressure measurement with mercury sphygmomanometer, patient observation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice President of Research Guilan university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-09</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for research, Shahid Siadati Avenue, Namjoo Street,Rasht Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
